LENZ Q4 2025 Results Align with Launch Baseline; DTC Impact Awaited

What happened

LENZ Therapeutics reported Q4 and full year 2025 financial results, confirming early commercial performance of VIZZ with $1.6 million net product revenue and over 45,000 paid prescriptions on pace through Q1 2026. This matches the baseline from the DeepValue report, which highlighted $1.6 million revenue and over 20,000 prescriptions in Q4 2025 as a starting point. The company emphasized broad prescriber uptake, with more than 10,000 eye care professionals, and encouraging refill trends, but these metrics are early and require validation. The direct-to-consumer campaign launched on January 14, 2026, is still in its initial phase, and its ability to drive revenue acceleration beyond this baseline remains unproven. Despite positive framing, safety concerns around retinal tear/detachment risks persist, as noted in the FDA label, and could dampen long-term adoption if not managed effectively.

Implication

The confirmed Q4 2025 baseline provides a measurable foundation, but it does not yet show the sequential acceleration needed to absorb the 88-territory sales force costs. Early prescription growth is positive, yet repeat prescribing behavior—critical for durability—must hold up beyond initial launch enthusiasm. Safety overhangs remain a key vulnerability, with any label tightening or adverse events likely to erode market sentiment and adoption quickly. Cash reserves of $188.9 million offer near-term protection, but failure to ramp revenue could force dilutive financing within the next year. Monitoring Q1 2026 revenue against the $4 million threshold and prescription persistence will be essential to determine if the bull case is materializing or if the bear scenario of flat growth is unfolding.

Thesis delta

The new information reinforces the existing thesis that LENZ's upside depends on revenue acceleration from the DTC campaign, with no material shift indicated as Q4 2025 data aligns with prior expectations. However, the on-pace prescription growth through Q1 2026 is a modest positive sign, though it falls short of the 50,000 prescription threshold needed for an upgrade. The call remains unchanged until Q1 2026 revenue is reported, with the bull case still contingent on meeting or exceeding $4 million to demonstrate meaningful demand inflection.